Observations of increased endogenous cortisol production and notable improvements in disease markers from the trial are seen as encouraging signs. The safety profile of BBP-613 was also favorable, showing no serious treatment-related adverse events. These factors, combined with improvements in functional outcomes from BBP-812 treated participants, underpin Zemansky's belief in the potential of BridgeBio Pharma's platform, despite the possibility that the company may opt to spin off or license it to focus on its late-stage pipeline. His maintained Buy rating and $42 price objective reflect an anticipation of value realization that the market has not yet fully appreciated.